Immunotherapy combined with chemotherapy for patients with pulmonary large cell neuroendocrine carcinoma  

作　　者：Jiaqi Li Haijiao Lu Tianqing Chu Fang Hu Jialin Qian Yinchen Shen 

机构地区：[1]Department of Respiratory and Critical Care Medicine,Shanghai Chest Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200030,China

出　　处：《Chinese Medical Journal》2024年第19期2384-2386,共3页中华医学杂志(英文版)

基　　金：funded by the Shanghai Committee of Science and Technology(No.21Y11913500);the National Health Commission Medical Science and Technology Development Research Center(No.WKZX2023CX030003).

摘　　要：To the Editor:Lung large cell neuroendocrine carcinoma(L-LCNEC)is a highly aggressive lung malignancy and accounts for nearly 2-3%of all lung cancers.The optimal therapeutic regimen for advanced or metastatic L-LCNEC is still controversial,especially in the era of immune checkpoint inhibitor(ICI)therapies.The existing clinical trials evaluating the efficacy of immunotherapy have mainly focused on patients with lung adenocarcinoma/squamous cell carcinoma or small cell lung cancer(SCLC).

关 键 词：LUNG PATIENTS LUNG 

分 类 号：R73[医药卫生—肿瘤]